Peringatan Keamanan

Overdosage with trospium is likely to result in anticholinergic adverse effects, which may include delirium, agitation, garbled speech, dizziness, hypertension, tachycardia, dry mouth, dry eyes, ileus, blurred vision, and urinary retention.L51629

Trospium

DB00209

small molecule approved

Deskripsi

Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.L6208 An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.L6208 Trospium is manufactured by Indevus Pharmaceutical Inc. and was granted FDA approval in 2007.L6211

Struktur Molekul 2D

Berat 392.518
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of trospium in patients receiving the extended-release formulation is approximately 35 hours,[L36823] whereas the half-life of immediate-release trospium is approximately 6 hours.[L51629]
Volume Distribusi The volume of distribution of orally administered trospium is approximately 531 liters.[L51629]
Klirens (Clearance) The total apparent clearance of trospium is 796 L/hour.[L51629] The renal clearance of trospium is 21 L/hour.[L51629]

Absorpsi

The mean absolute bioavailability of an orally administered immediate-release dose of trospium is approximately 9.6%.L36823

Metabolisme

Trospium is likely metabolized via ester hydrolysis and glucuronic acid conjugation, although its metabolic fate has not been fully characterized.L51629

Rute Eliminasi

After administration of oral 14C-trospium chloride, the majority of the dose (85.2%) was recovered in feces and a smaller amount (5.8% of the dose) was recovered in urine; 60% of the radioactivity excreted in urine was unchanged trospium. Trospium mainly undergoes elimination via active tubular secretion, as indicated by the mean renal clearance of 29.07 L/hour, which is about 4-fold higher than average glomerular filtration rate. Trospium is metabolized by ester hydrolysis and excreted by the kidneys by a combination of tubular secretion and glomerular filtration.

Interaksi Makanan

1 Data
  • 1. Take on an empty stomach. Take at least 1 hour before food as the Cmax and AUC of trospium are reduced by 70-80% when taken with a high fat meal.

Interaksi Obat

697 Data
Aclidinium The risk or severity of adverse effects can be increased when Trospium is combined with Aclidinium.
Metformin The serum concentration of Trospium can be decreased when it is combined with Metformin.
Mianserin Mianserin may increase the anticholinergic activities of Trospium.
Mirabegron The risk or severity of urinary retention can be increased when Trospium is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Trospium is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Trospium.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Trospium.
Tiotropium The risk or severity of adverse effects can be increased when Trospium is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Trospium is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Trospium is combined with Umeclidinium.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Trospium.
Glycopyrronium The risk or severity of adverse effects can be increased when Trospium is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Trospium is combined with Botulinum toxin type A.
Glucagon Trospium may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Trospium may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Trospium is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Trospium is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Trospium is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Trospium is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Trospium is combined with Bezitramide.
Morphine The risk or severity of adverse effects can be increased when Trospium is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Trospium is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Trospium is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Trospium is combined with Methadone.
Oxycodone The risk or severity of adverse effects can be increased when Trospium is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Trospium is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Trospium is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Trospium is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Trospium is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Trospium is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Trospium is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Trospium is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Trospium is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Trospium is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Trospium is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Trospium is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Trospium is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Trospium is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Trospium is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Trospium is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Trospium is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Trospium is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Trospium is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Trospium is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Trospium is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Trospium is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Trospium is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Trospium is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Trospium is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Trospium is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Trospium is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Trospium is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Trospium is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Trospium is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Trospium is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Trospium is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Trospium is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Trospium is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Trospium is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Trospium is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Trospium is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Trospium is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Trospium is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Trospium is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Trospium is combined with Carfentanil, C-11.
Meperidine The risk or severity of adverse effects can be increased when Trospium is combined with Meperidine.
Benzhydrocodone The risk or severity of adverse effects can be increased when Trospium is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Trospium is combined with Naloxegol.
Ethanol The risk or severity of drowsiness and CNS depression can be increased when Ethanol is combined with Trospium.
Oxyphenonium The risk or severity of adverse effects can be increased when Trospium is combined with Oxyphenonium.
Benzatropine The risk or severity of adverse effects can be increased when Trospium is combined with Benzatropine.
Disopyramide The risk or severity of adverse effects can be increased when Trospium is combined with Disopyramide.
Metixene The risk or severity of adverse effects can be increased when Trospium is combined with Metixene.
Buclizine The risk or severity of adverse effects can be increased when Trospium is combined with Buclizine.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trospium is combined with Trihexyphenidyl.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Trospium is combined with Oxyphencyclimine.
Procyclidine The risk or severity of adverse effects can be increased when Trospium is combined with Procyclidine.
Hyoscyamine The risk or severity of adverse effects can be increased when Trospium is combined with Hyoscyamine.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Trospium is combined with Methscopolamine bromide.
Darifenacin The risk or severity of adverse effects can be increased when Trospium is combined with Darifenacin.
Tridihexethyl The risk or severity of adverse effects can be increased when Trospium is combined with Tridihexethyl.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Trospium is combined with Anisotropine methylbromide.
Atropine The risk or severity of adverse effects can be increased when Trospium is combined with Atropine.
Nicardipine The risk or severity of adverse effects can be increased when Trospium is combined with Nicardipine.
Mecamylamine The risk or severity of adverse effects can be increased when Trospium is combined with Mecamylamine.
Pirenzepine The risk or severity of adverse effects can be increased when Trospium is combined with Pirenzepine.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Trospium is combined with Homatropine methylbromide.
Benzquinamide The risk or severity of adverse effects can be increased when Trospium is combined with Benzquinamide.
Propantheline The risk or severity of adverse effects can be increased when Trospium is combined with Propantheline.
Dicyclomine The risk or severity of adverse effects can be increased when Trospium is combined with Dicyclomine.
Tropicamide The risk or severity of adverse effects can be increased when Trospium is combined with Tropicamide.
Cocaine The risk or severity of adverse effects can be increased when Trospium is combined with Cocaine.
Quinidine The risk or severity of adverse effects can be increased when Trospium is combined with Quinidine.
Amantadine The risk or severity of adverse effects can be increased when Trospium is combined with Amantadine.
Methantheline The risk or severity of adverse effects can be increased when Trospium is combined with Methantheline.
Cycrimine The risk or severity of adverse effects can be increased when Trospium is combined with Cycrimine.
Cyclopentolate The risk or severity of adverse effects can be increased when Trospium is combined with Cyclopentolate.
Tolterodine The risk or severity of adverse effects can be increased when Trospium is combined with Tolterodine.
Oxybutynin The risk or severity of adverse effects can be increased when Trospium is combined with Oxybutynin.
Pentolinium The risk or severity of adverse effects can be increased when Trospium is combined with Pentolinium.

Target Protein

Muscarinic acetylcholine receptor M5 CHRM5
Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M1 CHRM1

Referensi & Sumber

Contoh Produk & Brand

Produk: 48 • International brands: 6
Produk
  • Accel-trospium
    Tablet • 20 mg • Oral • Canada • Generic • Approved
  • Cobenfy
    Capsule, coated pellets • - • Oral • US • Approved
  • Cobenfy
    Capsule, coated pellets • - • Oral • US • Approved
  • Cobenfy
    Capsule, coated pellets • - • Oral • US • Approved
  • Cobenfy
    Capsule, coated pellets; Kit • - • Oral • US • Approved
  • Cobenfy
    Capsule, coated pellets; Kit • - • Oral • US • Approved
  • Cobenfy
    Capsule, coated pellets; Kit • - • Oral • US • Approved
  • Cobenfy
    Capsule, coated pellets; Kit • - • Oral • US • Approved
Menampilkan 8 dari 48 produk.
International Brands
  • Flotros
  • Regurin
  • Spasmex
  • Spasmolyt
  • Spasmoplex
  • Tropez OD

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul